Bio Essence Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Bio Essence Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.90M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $323.9K | Mar 27, 2026 |
| FY2023 | Dec 31, 2023 | $551.5K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $621.6K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $888.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $958.7K | Mar 31, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.43M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $217.1K | Mar 27, 2026 |
| FY2023 | Dec 31, 2023 | $277.4K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $328.3K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $298.3K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $227.3K | Mar 31, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $896.2K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($1.31M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($971.9K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($809.7K) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($647.6K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($595.8K) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $900.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($459.4K) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($345.6K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($511.1K) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($857.5K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($832.6K) | Mar 31, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.57M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $623.9K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($1.03M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($703.2K) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($1.29M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($732.7K) | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $3.6K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.7K | Apr 15, 2024 |
| FY2021 | Dec 31, 2021 | $119.5K | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $7.4K | Mar 31, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $422.5K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $281.0K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.76M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.55M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.70M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.85M | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.50M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.25M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $4.42M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $4.79M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $4.13M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $3.63M | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.07M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($2.97M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | ($1.66M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | ($3.24M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | ($2.43M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | ($1.78M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($1.09M) | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.55M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($10.45M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($9.14M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($8.17M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($7.36M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($6.71M) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.4K | Mar 28, 2025 |
| FY2023 | Dec 31, 2023 | $114 | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $6.3K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $303 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.3K | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $16.2K | Mar 31, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.5K | Mar 27, 2026 |
| FY2024 | Dec 31, 2024 | $56.5K | Mar 28, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 38.01M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 38.01M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 38.01M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 33.01M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 33.01M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 33.01M | Mar 31, 2022 |